Developer docs
API playgroundTry for free, no card

Search company profiles

Nurix Therapeutics

Full company profile

uuid0000mri

Namestring
Nurix Therapeutics
Legal namestring
Nurix Therapeutics, Inc.
Websiteurl
nurixtx.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Nurix Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Brisbane, California (NASDAQ: NRIX). The company develops small-molecule drugs based on targeted protein degradation (TPD), an approach that uses the cell's own ubiquitin-proteasome system to eliminate disease-causing proteins rather than merely inhibiting them, and applies this approach to hematologic cancers, solid tumors, and autoimmune and inflammatory diseases. Its discovery engine, called DEL-AI, combines DNA-encoded library (DEL) screening of more than 5 billion chemical structures with automated chemistry and machine learning, and is supported by expertise in E3 ligase biology that has reportedly enabled over 90 distinct E3 ligases for drug discovery versus the two (cereblon and VHL) historically used in the field.

The pipeline is anchored by the oral BTK degrader bexobrutideg (NX-5948), which reported an 83% objective response rate in heavily pretreated relapsed/refractory CLL patients and entered a pivotal Phase 2 trial in late 2025, alongside a second BTK degrader (zelebrudomide/NX-2127) in Phase 1, the oral CBL-B inhibitor NX-1607 in Phase 1 for solid tumors, the partnered IRAK4 degrader GS-6791/NX-0479 with IND clearance in April 2025, the partnered STAT6 degrader NX-3911 with Sanofi, and earlier-stage oncology assets and a degrader-antibody conjugate (DAC) modality.

Nurix operates a partnership-driven business model: it generates revenue almost entirely from upfront payments, research funding, and milestone payments under collaborations with Roche (bexobrutideg, $700M upfront and up to $2.3B total), Gilead Sciences (IRAK4 program), Sanofi (STAT6 program), and Pfizer/Seagen (DACs), and finances clinical development through periodic public equity offerings (notably $250M in October 2025 and $175M in April 2024). The company plans to co-commercialize bexobrutideg directly in the United States while relying on partner infrastructure for ex-US markets, and reported $83.7M in annual operating revenue alongside a substantial operating loss and a Q1 2026 cash position of approximately $540.7M before the Roche payment.

Short descriptiontext

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for hematologic cancers, solid tumors, and autoimmune diseases using its proprietary DEL-AI platform that combines DNA-encoded libraries, machine learning, and E3 ligase biology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, biopharmaceutical drug discovery, BTK degrader therapeutics, E3 ligase modulators, degrader-antibody conjugates
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Targeted Protein Degradation Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership/Collaboration Revenue
TypeLicensing Royalties
Description

Nurix derives revenue primarily from strategic partnerships with pharmaceutical companies including Roche, Gilead, Sanofi, and Pfizer/Seagen. These partnerships provide upfront payments, milestone payments (development, regulatory, and commercial), and potential royalties on product sales. The company has secured over $3 billion in potential milestone value across partnerships.

in.investing.com
2Equity Financing
TypeOne Time License
Description

Pre-revenue clinical-stage company financed through public equity offerings. Completed $250M registered offering in October 2025, $175M in April 2024, and $40M in July 2022.

ad-hoc-news.de
3Research Funding
TypeSubscription Recurring
Description

Revenue from collaborative research arrangements with pharmaceutical partners funding specific research programs.

ad-hoc-news.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nurix Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule targeted protein degradation (degrader) medicines for hematologic cancers, solid tumors, and autoimmune/inflammatory diseases. Its core asset is the proprietary DEL-AI Discovery Engine that combines DNA-encoded libraries with machine learning to design novel degrader compounds, which feed a multi-asset pipeline (bexobrutideg, zelebrudomide, NX-1607, GS-6791, NX-3911, NRX-0305, NRX-4972, plus a DAC modality). The company monetizes these assets primarily through global partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen that generate upfront payments, R&D funding, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83% objective response rate in relapsed/refractory CLL patients with bexobrutideg (47 evaluable patients, median 3 prior therapies)
+3 more records
Product overview1 text field

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for cancer and autoimmune diseases. The company's platform, DEL-AI, combines DNA-encoded libraries with machine learning for drug discovery. The pipeline includes multiple degrader candidates: Bexobrutideg (BTK degrader, Phase 2 for CLL) and Zelebrudomide/NX-2127 (BTK degrader, Phase 1) for B-cell malignancies; NX-1607 (CBL-B inhibitor, Phase 1) for solid tumors; GS-6791 (IRAK4 degrader) for inflammation; and NRX-0305/NRX-4972 preclinical oncology programs. The company also develops Degrader-Antibody Conjugates (DACs). Strategic partnerships with Roche (up to $2.3B for bexobrutideg), Gilead (IRAK4 degrader), Sanofi (STAT6 degrader), and Pfizer/Seagen (DACs) validate the platform.

Product and service9 records
1DEL-AI Discovery Engine
CategoryDrug Discovery Platform / Technology
Description

Proprietary AI-powered drug discovery platform that integrates DNA-encoded library (DEL) screening data, automated chemistry, and machine learning to identify and optimize novel targeted protein degrader compounds; features more than 5 billion unique chemical structures and has enabled more than 90 distinct E3 ligases for drug discovery. The platform underpins all of Nurix's internal pipeline and is the foundation of its partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen.

2Bexobrutideg (NX-5948)
CategoryClinical-Stage Drug Candidate (BTK Degrader)
Description

Oral, blood-brain barrier-penetrating BTK degrader in pivotal Phase 2 (DAYBreak) development for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with Phase 1 expansion into Waldenström macroglobulinemia, DLBCL, MCL, MZL, FL, PCNSL, and autoimmune indications including chronic spontaneous urticaria. Demonstrated an 83% objective response rate in 47 evaluable CLL patients (median 3 prior therapies) and 75% ORR in Waldenström macroglobulinemia. Subject of a global co-development and co-commercialization agreement with Roche worth up to $2.3 billion announced in June 2026.

3Zelebrudomide (NX-2127)
CategoryClinical-Stage Drug Candidate (BTK Degrader)
Description

Oral BTK degrader in Phase 1 clinical development for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and other hematologic cancers. Earlier-stage BTK degrader program that complements bexobrutideg within Nurix's B-cell malignancy strategy.

4NX-1607
CategoryClinical-Stage Drug Candidate (CBL-B Inhibitor)
Description

Oral CBL-B inhibitor in Phase 1 clinical development for patients with advanced malignancies, including ovarian, gastric, head and neck, melanoma, non-small cell lung cancer, prostate, breast, and urothelial cancers. Phase 1 data demonstrated immune activation and tumor microenvironment remodeling, supporting its role in immuno-oncology combination strategies.

5GS-6791 / NX-0479 (IRAK4 Degrader)
CategoryClinical-Stage Drug Candidate (IRAK4 Degrader)
Description

IRAK4 degrader for inflammatory diseases that received FDA IND clearance in April 2025 and is now in Phase 1 clinical trials. Developed under the global strategic collaboration with Gilead Sciences (originally signed 2019, expanded in 2024), with Gilead having exercised its option to exclusively license the program in 2023.

6NX-3911 (STAT6 Degrader)
CategoryPreclinical Drug Candidate (STAT6 Degrader)
Description

STAT6 degrader for inflammatory diseases, advancing through IND-enabling studies under the global strategic collaboration with Sanofi. Sanofi exercised its license extension option to the program in 2025 and has assumed the cost of IND-enabling studies. The program targets Th2-mediated inflammatory diseases where disruption of IL-4/IL-13 signaling via STAT6 degradation may provide differentiated efficacy.

7NRX-0305 (Pan-mutant BRAF Degrader)
CategoryPreclinical Drug Candidate (BRAF Degrader)
Description

Pan-mutant BRAF degrader for melanoma (including brain metastases) and other BRAF-driven cancers. Preclinical data presented at AACR 2026 demonstrated a 142% lifespan increase versus 12% for dabrafenib in a melanoma brain metastasis model, supporting its potential as a differentiated therapy for BRAF-mutant tumors, including those that have metastasized to the brain.

8NRX-4972 (Aurora Kinase A Degrader)
CategoryPreclinical Drug Candidate (Aurora Kinase A Degrader)
Description

Aurora Kinase A degrader for oncology applications. Preclinical data were presented at the AACR 2026 annual meeting, supporting its development for tumors dependent on Aurora Kinase A activity, where targeted degradation may offer improved selectivity and durability over traditional kinase inhibitors.

9Degrader-Antibody Conjugates (DACs)
CategoryTherapeutic Modality (Degrader-Antibody Conjugates)
Description

Innovative therapeutic modality that combines the cell-targeting specificity of monoclonal antibodies with the potency, selectivity, and catalytic activity of targeted protein degraders, with the goal of producing cancer medicines with enhanced precision and improved safety. Developed as a new therapeutic class under the Seagen/Pfizer collaboration announced in 2023.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Global collaboration to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell malignancies, immunology, and neurology indications. Roche pays $700M upfront with potential total deal value up to $2.3B. Development costs split 60/40 (Roche/Nurix). US profits shared equally; Roche handles ex-US commercialization with royalties to Nurix.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Strategic collaboration with Seagen (now part of Pfizer) to advance degrader antibody conjugates (DACs) as an innovative new class of cancer therapeutics combining antibody specificity with degrader potency.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Expanded in 2021. Sanofi exercises license extension option to STAT6 program (2025). STAT6 degrader NX-3911 in IND-enabling studies with Sanofi assuming IND-enabling costs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Gilead exercised option to exclusively license Nurix's IRAK4 degrader (2023). Collaboration extended in 2024. IRAK4 degrader GS-6791/NX-0479 in Phase 1 clinical trials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in targeted protein degradation using PROTAC technology for cancer and other diseases. Direct competitor to Nurix in the protein degrader space with overlapping BTK and other oncology programs. Arvinas has multiple clinical-stage assets and established pharma partnerships, making it the most directly comparable peer.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing targeted protein degraders with a proprietary Pegasus platform. Direct competitor in BTK and immunology degrader space; both companies compete for the same target classes and partnership economics with major pharma.

TypeDirect peer
Description

Clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and other diseases. Direct peer in the targeted protein degradation space with a different but overlapping modality (glue degraders vs. PROTACs) addressing similar oncology and immunology indications.

TypeDirect peer
Description

Clinical-stage company developing small-molecule degraders using its TORPEDO platform for cancer and neurodegenerative diseases. Direct peer competing in the degrader space with multiple clinical-stage assets and pharma partnerships.

TypeDirect peer
Description

Clinical-stage biotech targeting chromatin regulatory biology, including protein degradation approaches for cancer. Direct competitor with overlapping oncology focus and similar clinical-stage profile as Nurix.

TypeEmerging player
Description

Privately held biotech co-founded by protein degradation pioneer Ray Deshaies focused on next-generation molecular glue degraders. Emerging player in the same degrader space, comparable through shared focus on E3 ligase-enabled targeted protein degradation.

TypeEmerging player
Description

Emerging biotech developing LYTACs (lysosome-targeting chimeras), an alternative degradation modality. Comparable to Nurix through shared focus on expanding the druggable protein universe via novel degradation approaches.

TypeEmerging player
Description

Protein degradation-focused biotech (now part of Incyte) with a molecular glue approach to challenging oncology targets. Comparable through shared focus on E3 ligase-based protein degraders for hematology and oncology.

TypeBroad incumbent
Description

Major pharmaceutical company that is both a Nurix partner (via Seagen acquisition, for DACs) and a broad incumbent in hematology/oncology with internal degrader-adjacent programs and competing BTK inhibitors. Comparable through overlap in target indications and partnership dynamics.

TypeBroad incumbent
Description

Large biopharmaceutical incumbent with established presence in hematology/oncology and biologics manufacturing. Comparable through overlapping therapeutic focus on B-cell malignancies and inflammation, plus broader infrastructure that competes with Nurix's partnered programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nurix Therapeutics

Targeted Protein Degradation Biopharmaceuticalsnurixtx.com

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for hematologic cancers, solid tumors, and autoimmune diseases using its proprietary DEL-AI platform that combines DNA-encoded libraries, machine learning, and E3 ligase biology.

What Nurix Therapeutics does

Nurix Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Brisbane, California (NASDAQ: NRIX). The company develops small-molecule drugs based on targeted protein degradation (TPD), an approach that uses the cell's own ubiquitin-proteasome system to eliminate disease-causing proteins rather than merely inhibiting them, and applies this approach to hematologic cancers, solid tumors, and autoimmune and inflammatory diseases. Its discovery engine, called DEL-AI, combines DNA-encoded library (DEL) screening of more than 5 billion chemical structures with automated chemistry and machine learning, and is supported by expertise in E3 ligase biology that has reportedly enabled over 90 distinct E3 ligases for drug discovery versus the two (cereblon and VHL) historically used in the field.

The pipeline is anchored by the oral BTK degrader bexobrutideg (NX-5948), which reported an 83% objective response rate in heavily pretreated relapsed/refractory CLL patients and entered a pivotal Phase 2 trial in late 2025, alongside a second BTK degrader (zelebrudomide/NX-2127) in Phase 1, the oral CBL-B inhibitor NX-1607 in Phase 1 for solid tumors, the partnered IRAK4 degrader GS-6791/NX-0479 with IND clearance in April 2025, the partnered STAT6 degrader NX-3911 with Sanofi, and earlier-stage oncology assets and a degrader-antibody conjugate (DAC) modality.

Nurix operates a partnership-driven business model: it generates revenue almost entirely from upfront payments, research funding, and milestone payments under collaborations with Roche (bexobrutideg, $700M upfront and up to $2.3B total), Gilead Sciences (IRAK4 program), Sanofi (STAT6 program), and Pfizer/Seagen (DACs), and finances clinical development through periodic public equity offerings (notably $250M in October 2025 and $175M in April 2024). The company plans to co-commercialize bexobrutideg directly in the United States while relying on partner infrastructure for ex-US markets, and reported $83.7M in annual operating revenue alongside a substantial operating loss and a Q1 2026 cash position of approximately $540.7M before the Roche payment.

Nurix Therapeutics firmographics

Firmographics
Name
Nurix Therapeutics
Legal name
Nurix Therapeutics, Inc.
Website
https://nurixtx.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
251–500 employees
Short description
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for hematologic cancers, solid tumors, and autoimmune diseases using its proprietary DEL-AI platform that combines DNA-encoded libraries, machine learning, and E3 ligase biology.
Ownership category
akta.pro rank

Nurix Therapeutics industry classification

Industry
Product category
Targeted Protein Degradation Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Targeted protein degradation
  • Biopharmaceutical drug discovery
  • BTK degrader therapeutics
  • E3 ligase modulators
  • Degrader-antibody conjugates

Where Nurix Therapeutics is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nurix Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership/Collaboration Revenue: Nurix derives revenue primarily from strategic partnerships with pharmaceutical companies including Roche, Gilead, Sanofi, and Pfizer/Seagen. These partnerships provide upfront payments, milestone payments (development, regulatory, and commercial), and potential royalties on product sales. The company has secured over $3 billion in potential milestone value across partnerships.
  2. Equity Financing: Pre-revenue clinical-stage company financed through public equity offerings. Completed $250M registered offering in October 2025, $175M in April 2024, and $40M in July 2022.
  3. Research Funding: Revenue from collaborative research arrangements with pharmaceutical partners funding specific research programs.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Nurix Therapeutics product offering

Product offering

Core offering

Nurix Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule targeted protein degradation (degrader) medicines for hematologic cancers, solid tumors, and autoimmune/inflammatory diseases. Its core asset is the proprietary DEL-AI Discovery Engine that combines DNA-encoded libraries with machine learning to design novel degrader compounds, which feed a multi-asset pipeline (bexobrutideg, zelebrudomide, NX-1607, GS-6791, NX-3911, NRX-0305, NRX-4972, plus a DAC modality). The company monetizes these assets primarily through global partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen that generate upfront payments, R&D funding, milestones, and royalties.

Product overview

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for cancer and autoimmune diseases. The company's platform, DEL-AI, combines DNA-encoded libraries with machine learning for drug discovery. The pipeline includes multiple degrader candidates: Bexobrutideg (BTK degrader, Phase 2 for CLL) and Zelebrudomide/NX-2127 (BTK degrader, Phase 1) for B-cell malignancies; NX-1607 (CBL-B inhibitor, Phase 1) for solid tumors; GS-6791 (IRAK4 degrader) for inflammation; and NRX-0305/NRX-4972 preclinical oncology programs. The company also develops Degrader-Antibody Conjugates (DACs). Strategic partnerships with Roche (up to $2.3B for bexobrutideg), Gilead (IRAK4 degrader), Sanofi (STAT6 degrader), and Pfizer/Seagen (DACs) validate the platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • DEL-AI Discovery Engine Proprietary AI-powered drug discovery platform that integrates DNA-encoded library (DEL) screening data, automated chemistry, and machine learning to identify and optimize novel targeted protein degrader compounds; features more than 5 billion unique chemical structures and has enabled more than 90 distinct E3 ligases for drug discovery. The platform underpins all of Nurix's internal pipeline and is the foundation of its partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen.
  • Bexobrutideg (NX-5948) Oral, blood-brain barrier-penetrating BTK degrader in pivotal Phase 2 (DAYBreak) development for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with Phase 1 expansion into Waldenström macroglobulinemia, DLBCL, MCL, MZL, FL, PCNSL, and autoimmune indications including chronic spontaneous urticaria. Demonstrated an 83% objective response rate in 47 evaluable CLL patients (median 3 prior therapies) and 75% ORR in Waldenström macroglobulinemia. Subject of a global co-development and co-commercialization agreement with Roche worth up to $2.3 billion announced in June 2026.
  • Zelebrudomide (NX-2127) Oral BTK degrader in Phase 1 clinical development for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and other hematologic cancers. Earlier-stage BTK degrader program that complements bexobrutideg within Nurix's B-cell malignancy strategy.
  • NX-1607 Oral CBL-B inhibitor in Phase 1 clinical development for patients with advanced malignancies, including ovarian, gastric, head and neck, melanoma, non-small cell lung cancer, prostate, breast, and urothelial cancers. Phase 1 data demonstrated immune activation and tumor microenvironment remodeling, supporting its role in immuno-oncology combination strategies.
  • GS-6791 / NX-0479 (IRAK4 Degrader) IRAK4 degrader for inflammatory diseases that received FDA IND clearance in April 2025 and is now in Phase 1 clinical trials. Developed under the global strategic collaboration with Gilead Sciences (originally signed 2019, expanded in 2024), with Gilead having exercised its option to exclusively license the program in 2023.
  • NX-3911 (STAT6 Degrader) STAT6 degrader for inflammatory diseases, advancing through IND-enabling studies under the global strategic collaboration with Sanofi. Sanofi exercised its license extension option to the program in 2025 and has assumed the cost of IND-enabling studies. The program targets Th2-mediated inflammatory diseases where disruption of IL-4/IL-13 signaling via STAT6 degradation may provide differentiated efficacy.
  • NRX-0305 (Pan-mutant BRAF Degrader) Pan-mutant BRAF degrader for melanoma (including brain metastases) and other BRAF-driven cancers. Preclinical data presented at AACR 2026 demonstrated a 142% lifespan increase versus 12% for dabrafenib in a melanoma brain metastasis model, supporting its potential as a differentiated therapy for BRAF-mutant tumors, including those that have metastasized to the brain.
  • NRX-4972 (Aurora Kinase A Degrader) Aurora Kinase A degrader for oncology applications. Preclinical data were presented at the AACR 2026 annual meeting, supporting its development for tumors dependent on Aurora Kinase A activity, where targeted degradation may offer improved selectivity and durability over traditional kinase inhibitors.
  • Degrader-Antibody Conjugates (DACs) Innovative therapeutic modality that combines the cell-targeting specificity of monoclonal antibodies with the potency, selectivity, and catalytic activity of targeted protein degraders, with the goal of producing cancer medicines with enhanced precision and improved safety. Developed as a new therapeutic class under the Seagen/Pfizer collaboration announced in 2023.

Quantifiable outcome

  • 83% objective response rate in relapsed/refractory CLL patients with bexobrutideg (47 evaluable patients, median 3 prior therapies)
  • +3 more outcomes

Companies that use Nurix Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Nurix Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Nurix Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • RochecoreStrategic or Co-development Partner · 8 June 2026Global collaboration to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell malignancies, immunology, and neurology indications. Roche pays $700M upfront with potential total deal value up to $2.3B. Development costs split 60/40 (Roche/Nurix). US profits shared equally; Roche handles ex-US commercialization with royalties to Nurix.
  • Pfizer (formerly Seagen)minorStrategic or Co-development Partner · 1 January 2023Strategic collaboration with Seagen (now part of Pfizer) to advance degrader antibody conjugates (DACs) as an innovative new class of cancer therapeutics combining antibody specificity with degrader potency.
  • SanoficoreStrategic or Co-development Partner · 1 January 2020Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Expanded in 2021. Sanofi exercises license extension option to STAT6 program (2025). STAT6 degrader NX-3911 in IND-enabling studies with Sanofi assuming IND-enabling costs.
  • Gilead SciencescoreStrategic or Co-development Partner · 1 January 2019Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Gilead exercised option to exclusively license Nurix's IRAK4 degrader (2023). Collaboration extended in 2024. IRAK4 degrader GS-6791/NX-0479 in Phase 1 clinical trials.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Nurix Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Pioneer in targeted protein degradation using PROTAC technology for cancer and other diseases. Direct competitor to Nurix in the protein degrader space with overlapping BTK and other oncology programs. Arvinas has multiple clinical-stage assets and established pharma partnerships, making it the most directly comparable peer.
  • Kymera Therapeutics: Clinical-stage biopharmaceutical company developing targeted protein degraders with a proprietary Pegasus platform. Direct competitor in BTK and immunology degrader space; both companies compete for the same target classes and partnership economics with major pharma.
  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and other diseases. Direct peer in the targeted protein degradation space with a different but overlapping modality (glue degraders vs. PROTACs) addressing similar oncology and immunology indications.
  • C4 Therapeutics: Clinical-stage company developing small-molecule degraders using its TORPEDO platform for cancer and neurodegenerative diseases. Direct peer competing in the degrader space with multiple clinical-stage assets and pharma partnerships.
  • Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory biology, including protein degradation approaches for cancer. Direct competitor with overlapping oncology focus and similar clinical-stage profile as Nurix.

Emerging players

  • Neomorph: Privately held biotech co-founded by protein degradation pioneer Ray Deshaies focused on next-generation molecular glue degraders. Emerging player in the same degrader space, comparable through shared focus on E3 ligase-enabled targeted protein degradation.
  • Lycia Therapeutics: Emerging biotech developing LYTACs (lysosome-targeting chimeras), an alternative degradation modality. Comparable to Nurix through shared focus on expanding the druggable protein universe via novel degradation approaches.
  • BioTheryX (acquired by Incyte): Protein degradation-focused biotech (now part of Incyte) with a molecular glue approach to challenging oncology targets. Comparable through shared focus on E3 ligase-based protein degraders for hematology and oncology.

Broad incumbents

  • Pfizer: Major pharmaceutical company that is both a Nurix partner (via Seagen acquisition, for DACs) and a broad incumbent in hematology/oncology with internal degrader-adjacent programs and competing BTK inhibitors. Comparable through overlap in target indications and partnership dynamics.
  • Amgen: Large biopharmaceutical incumbent with established presence in hematology/oncology and biologics manufacturing. Comparable through overlapping therapeutic focus on B-cell malignancies and inflammation, plus broader infrastructure that competes with Nurix's partnered programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Nurix Therapeutics social profiles

Digital presence

Nurix Therapeutics compliance and trust

Trust signal

Compliance3 records

Nurix Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nurix Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Nurix Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nurix Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nurix Therapeutics

What does Nurix Therapeutics do?

Nurix Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule targeted protein degradation (degrader) medicines for hematologic cancers, solid tumors, and autoimmune/inflammatory diseases. Its core asset is the proprietary DEL-AI Discovery Engine that combines DNA-encoded libraries with machine learning to design novel degrader compounds, which feed a multi-asset pipeline (bexobrutideg, zelebrudomide, NX-1607, GS-6791, NX-3911, NRX-0305, NRX-4972, plus a DAC modality). The company monetizes these assets primarily through global partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen that generate upfront payments, R&D funding, milestones, and royalties.

Is Nurix Therapeutics a public or private company?

Nurix Therapeutics is a public company. It is classified as public and is currently operating.

When was Nurix Therapeutics founded?

Nurix Therapeutics was founded in 2012. It employs 251 to 500 people.

Where is Nurix Therapeutics based?

Nurix Therapeutics is headquartered in Brisbane, United States, in the North America region.

How does Nurix Therapeutics make money?

Three revenue lines are on record. Partnership/Collaboration Revenue is the primary driver. The others are equity Financing and research Funding.

Who are Nurix Therapeutics's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, Monte Rosa Therapeutics, C4 Therapeutics and Foghorn Therapeutics. Emerging players are Neomorph, Lycia Therapeutics and BioTheryX (acquired by Incyte). Broad incumbents are Pfizer and Amgen.

Does Nurix Therapeutics have an API?

No public API is recorded for Nurix Therapeutics.

What industry is Nurix Therapeutics in?

Nurix Therapeutics's product category is Targeted Protein Degradation Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comNurix Therapeutics stock hits 52-week low at $13.64Nurix Therapeutics stock hit a 52-week low of $13.64, down 52% from its high of $28.23. The company reported a Q3 net gain of $4.73 per share and $673.1 million in collaboration revenue, while analysts have mixed price targets, with H.C. Wainwright and Stifel raising theirs.Investing.comNurix therapeutics at jefferies healthcare conference: pipeline momentum buildsNurix Therapeutics presented its BTK degrader bexobrutideg at the Jefferies Healthcare Conference, citing an 85% objective response rate and 22.1-month progression-free survival in later-line CLL. The company started a phase III trial of about 620 patients against pirtobrutinib, with enrollment expected to finish in 2027. It also advanced immunology programs, including a Gilead IRAK4 degrader nearing phase I completion.Seeking AlphaNurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 TranscriptNurix Therapeutics CEO Arthur Sands presented at the UBS Global Biopharma Conference, focusing on its targeted protein degradation platform. The company's lead program, bexobrutideg (BEXdeg), a BTK degrader, is in Phase III and expanding with Roche. Updates are expected over the next 6 to 12 months.Simply Wall StHow Investors Are Reacting To Nurix Therapeutics (NRIX) CMO AppointmentNurix Therapeutics appointed Arati V. Rao as CMO and reported that partner Sanofi ended the SAR448272 STAT6 degrader program, removing up to about US$453 million in milestones and royalties. The company's Q2 2026 revenue was US$9.0 million with a net loss of US$89.5 million, and its bexobrutideg alliance with Roche includes a US$700 million upfront payment.TradingViewNurix Therapeutics stock is up, what you need to knowNurix Therapeutics shares rose 3.4% after appointing Arati Rao as chief medical officer to oversee clinical development of its bexobrutigdeg BTK degrader. The stock closed at $16.33, up 2.8% from the previous close, and the company has $1.1 billion in cash and marketable securities.Stock TitanNurix Appoints Arati Rao as Chief Medical OfficerNurix Therapeutics appointed Arati V. Rao, M.D., as chief medical officer to lead its clinical development organization. She brings over 20 years of experience in oncology and clinical development, previously at Pfizer and Kite-Gilead. She will advance bexobrutideg with Roche and Nurix's broader pipeline.Stock TitanNurix Therapeutics to join 3 investor conferencesNurix Therapeutics announced management will participate in fireside chats at the UBS Global Biopharma, Jefferies Global Healthcare, and Piper Sandler Annual Healthcare conferences. The chats are webcast live and archived for 30 days. The company's pipeline includes bexobrutideg with Roche and a CBL-B inhibitor.YahooIs Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?Nurix Therapeutics reported Sanofi terminated its Phase 1 trial of the STAT6 degrader SAR448272, while new Phase 1a/1b data for bexobrutideg in relapsed CLL/SLL showed high response rates and tolerability. The loss of one program reduces collaboration inflows, but the bexobrutideg data supports prioritizing that candidate for future partnering and development.Simply Wall StNurix Therapeutics (NRIX) Gains On Bexobrutideg Data As Fair Value Debate ReturnsNurix Therapeutics reported Phase 1a/1b data for bexobrutideg at the 68th ASH meeting, showing high response rates and favorable tolerability in relapsed/refractory CLL/SLL. Shares closed at $15.30, down 42.9% over seven days, while a consensus fair value of $34.50 suggests undervaluation. The Roche collaboration includes a $700 million upfront payment and up to $2.3 billion in milestones.